Sort by
Refine Your Search
-
Research Fellow (Fusion Shielding Materials) - School of Metallurgy and Materials - 105638 - Grade 7
analytical capability Ability to communicate complex information clearly Fluency in relevant models, techniques or methods and ability to contribute to developing new methods Ability to assess resource
-
microbial genetics and sequencing High level analytical capability Ability to communicate complex information clearly Ability to contribute to developing new protocols and techniques Ability to assess
-
using flow cytometry to analyse in vivo immune responses High level analytical capability Ability to communicate complex information clearly Ability to contribute to developing new protocols and
-
of health IT solutions. Collaborate with cross-functional teams, including clinicians, analysts, clinical operations, and quality and safety leaders to address complex healthcare informatics challenges
-
Performance Computer Publication record appropriate to experience Ability to communicate complex information clearly Ability to assess resource requirements and use resources effectively Understanding of and
-
Position Details School of Computer Science Location: University of Birmingham, Edgbaston, Birmingham UK Full time starting salary is normally in the range £36,130 to £45,413 with potential
-
once in post to £48,149 Grade: 7 Full Time, Fixed Term contract up to August 2028 Closing date: 25th July 2025 Background We are seeking an innovative Research Fellow in Computational Metabolomics
-
to the creation of knowledge by undertaking a specified range of activities within an established research programme and/or specific research project. Our international group of highly motivated and
-
research spaces for academics and their collaborators. In addition, the University of Birmingham offers exceptional High Performance Computing facilities, including through the Tier-2 Baskerville system
-
oncology grouping sees close to 550 new cases of these cancers a year. There is a large active clinical trials programme that spans phase 1 to phase 3. These patients have a poor prognosis, and this clinic